CSP Specialty Drug Therapies & Disease Management 2

Question 1

Imatinib exerts its therapeutic effect in chronic myeloid leukemia primarily by inhibiting which target?

Accepted Answer

BCR-ABL tyrosine kinase

Answer

Imatinib inhibits the constitutively active BCR-ABL tyrosine kinase produced by the Philadelphia chromosome.

Question 2

Which oral chemotherapy agent carries a boxed warning for increased bleeding risk and INR elevation when given with warfarin?

Accepted Answer

Capecitabine

Answer

Capecitabine can markedly raise INR in patients on warfarin, so frequent INR monitoring is required.

Question 3

Before lenalidomide can be dispensed, which requirement must be satisfied?

Accepted Answer

Prescriber, patient, and pharmacy must be enrolled in the lenalidomide REMS program

Answer

Lenalidomide is distributed under a REMS due to embryo-fetal toxicity, requiring certified prescribers, pharmacies, and enrolled patients.

Question 4

A patient with CLL on ibrutinib reports palpitations. Which adverse effect of ibrutinib is most likely responsible?

Accepted Answer

Atrial fibrillation

Answer

Ibrutinib is associated with atrial fibrillation and bleeding risk.

Question 5

Osimertinib is preferred in non-small cell lung cancer harboring which mutation, including resistance mutations?

Accepted Answer

EGFR mutations including T790M

Answer

Osimertinib is a third-generation EGFR TKI active against sensitizing EGFR mutations and T790M resistance.

CSP - Certified Specialty Pharmacist Practice Test